Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis 1 COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVI-19.
| Market Cap | 13.406 Million | Shares Outstanding | 1.819 Million | Avg 30-day Volume | 31.722 Thousand |
| P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -14.44 |
| Price to Revenue | 4.5878 | Debt to Equity | 0.0 | EBITDA | -82.458 Million |
| Price to Book Value | 0.1361 | Operating Margin | -3165.7433 | Enterprise Value | -86.123 Million |
| Current Ratio | 11.009 | EPS Growth | 0.325 | Quick Ratio | 10.66 |
| 1 Yr BETA | -4.9182 | 52-week High/Low | 9.75 / 4.35 | Profit Margin | -3008.9411 |
| Operating Cash Flow Growth | 64.0825 | Free Cash Flow to Firm (FCFF) TTM | -48.511 Million | Free Cash Flow to Equity (FCFE) TTM | -64.619 Million |
| Altman Z-Score | -7.0127 |
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
LUKOWIAK ANDREW A PRESIDENT |
|
0 | 2023-08-01 | 2 |
|
MARKOVICH REBECCA INTERIM CFO |
|
0 | 2023-07-17 | 2 |
|
0 | 2023-06-09 | 1 | |
|
0 | 2023-06-09 | 1 | |
|
0 | 2023-06-09 | 1 | |
|
0 | 2023-06-09 | 3 | |
|
0 | 2023-06-09 | 1 | |
|
0 | 2023-06-09 | 1 | |
|
0 | 2023-06-09 | 1 | |
|
MOODY JOHN ROGER JR CHIEF FINANCIAL OFFICER |
|
0 | 2023-04-07 | 1 |
|
KELLEY ROBERT J. CHIEF EXECUTIVE OFFICER |
|
0 | 2023-04-07 | 1 |
|
0 | 2023-03-10 | 1 | |
|
BLASER BRIAN J PRESIDENT AND CEO |
|
1,375,000 | 2021-12-01 | 0 |
|
LIU DOUGLAS CHIEF OPERATING OFFICER |
|
514,685 | 2021-10-02 | 0 |
|
38,619 | 2021-08-13 | 0 | |
|
0 | 2021-03-16 | 0 | |
|
COE BRIAN CHIEF EXECUTIVE OFFICER |
|
96,283 | 2021-02-17 | 0 |
|
FLICK KAREN E. CHIEF OF STAFF, SR. VP, LEGAL |
|
2,000 | 2021-02-17 | 0 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | ||||||||||||||||
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|---|---|---|---|
| TALIS BIOMEDICAL CORP TLIS | 2023-11-28 22:15:04 UTC | -10.5665 | 15.8865 | 150000 |
| TALIS BIOMEDICAL CORP TLIS | 2023-11-28 21:45:03 UTC | -10.5665 | 15.8865 | 150000 |
| TALIS BIOMEDICAL CORP TLIS | 2023-11-28 21:15:04 UTC | -10.5665 | 15.8865 | 150000 |
| TALIS BIOMEDICAL CORP TLIS | 2023-11-28 20:45:04 UTC | -10.5665 | 15.8865 | 150000 |
| TALIS BIOMEDICAL CORP TLIS | 2023-11-28 20:15:04 UTC | -10.5665 | 15.8865 | 150000 |
| TALIS BIOMEDICAL CORP TLIS | 2023-11-28 19:45:03 UTC | -10.5665 | 15.8865 | 150000 |
| TALIS BIOMEDICAL CORP TLIS | 2023-11-28 19:15:04 UTC | -10.5665 | 15.8865 | 150000 |
| TALIS BIOMEDICAL CORP TLIS | 2023-11-28 18:45:03 UTC | -10.5665 | 15.8865 | 150000 |
| TALIS BIOMEDICAL CORP TLIS | 2023-11-28 18:15:03 UTC | -10.5665 | 15.8865 | 150000 |
| TALIS BIOMEDICAL CORP TLIS | 2023-11-28 17:45:04 UTC | -10.5665 | 15.8865 | 150000 |
| TALIS BIOMEDICAL CORP TLIS | 2023-11-28 17:15:04 UTC | -10.5665 | 15.8865 | 150000 |
| TALIS BIOMEDICAL CORP TLIS | 2023-11-28 16:45:04 UTC | -10.5665 | 15.8865 | 150000 |
| TALIS BIOMEDICAL CORP TLIS | 2023-11-28 16:15:04 UTC | -10.5665 | 15.8865 | 150000 |
| TALIS BIOMEDICAL CORP TLIS | 2023-11-28 15:45:03 UTC | -10.5665 | 15.8865 | 150000 |
| TALIS BIOMEDICAL CORP TLIS | 2023-11-28 15:15:03 UTC | -10.5665 | 15.8865 | 150000 |
| TALIS BIOMEDICAL CORP TLIS | 2023-11-28 14:45:04 UTC | -10.5665 | 15.8865 | 150000 |
| TALIS BIOMEDICAL CORP TLIS | 2023-11-28 14:15:04 UTC | -10.5665 | 15.8865 | 150000 |
| TALIS BIOMEDICAL CORP TLIS | 2023-11-28 13:45:04 UTC | -10.3402 | 15.6602 | 150000 |
| TALIS BIOMEDICAL CORP TLIS | 2023-11-28 13:15:03 UTC | -10.3402 | 15.6602 | 150000 |
| TALIS BIOMEDICAL CORP TLIS | 2023-11-28 12:45:04 UTC | -10.3402 | 15.6602 | 150000 |
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|
